Enable JavaScript to visit this website.

Referenties - Patient - Dutch

Referenties

REFERENTIES

  1. Adams D. et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016, 29 (suppl 1):S14–S26.
  2. Pinney JH, Hawkins PN. Amyloidosis. Ann Clin Biochem. 2012;49(Pt 3):229-41
  3. ATTR amyloidosis. http://www.amyloidosis.org.uk (geraadpleegd op 05/05/2019)
  4. Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(suppl 7):S107-S112.
  5. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
  6. Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-172

190332/Maart 2019

Normal

Copyright© 2020 Pfizer NV. Alle rechten voorbehouden.